Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
63 studies found for:    (lymphoma [CONDITION] OR CLL [CONDITION]) AND Lenalidomide [TREATMENT] | Open Studies
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Recruiting Lenalidomide, MTX, Ara-C and Rituximab in Relapsed Aggressive B-cell Lymphomas
Condition: B-cell Lymphoma
Intervention: Drug: Lenalidomide
2 Recruiting Efficacy of a Treatment With CHOP and Lenalidomide in First Line in Angioimmunoblastic T-cell Lymphoma (AITL)
Condition: T-cell Lymphoma
Intervention: Drug: Lenalidomide
3 Recruiting Study of Obinutuzumab and Lenalidomide in Previously Untreated Subjects With Follicular Lymphoma
Condition: Follicular Lymphoma
Interventions: Drug: Obinutuzumab;   Drug: Lenalidomide
4 Recruiting Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.
Condition: Lymphoma, Non-Hodgkin
Interventions: Drug: Lenalidomide;   Drug: Rituximab
5 Recruiting Safety and Efficacy of Revlimid® (Lenalidomide) With Mabthera® (Rituximab) in Non-Hodgkin's Lymphoma
Condition: Non-Hodgkin Lymphoma
Intervention: Drug: Lenalidomide/Rituximab
6 Recruiting Lenalidomide and GA101 in Relapsed Indolent Non-Hodgkin's Lymphoma
Condition: Lymphoma
Interventions: Drug: Lenalidomide;   Drug: Obinutuzumab (GA101)
7 Not yet recruiting Lenalidomide, Ixazomib, and Rituximab as Front-Line Therapy for High Risk Indolent B-Cell Lymphoma
Conditions: B Cell Lymphoma;   Lymphoma
Interventions: Drug: Ixazomib;   Drug: Lenalidomide;   Drug: Rituximab
8 Recruiting Phase I/II Carfilzomib Plus Lenalidomide and Rituximab in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma
Condition: Lymphoma
Interventions: Drug: Carfilzomib;   Drug: Lenalidomide;   Drug: Rituximab
9 Recruiting A Combination of Lenalidomide and Rituximab as Front Line Therapy for the Treatment of Elderly Frail Patients Evaluated in CGA With Diffuse Large B-cells Non-Hodgkin Lymphoma. A Phase II Study of the Fondazione Italiana Linfomi (FIL)
Condition: Diffuse Large B-cells Non-Hodgkin Lymphoma
Intervention: Drug: Rituximab-Dexamethasone-Lenalidomide
10 Recruiting Study of OBINUTUZUMAB Combined to LENALIDOMIDE for the Treatment of Relapsed/Refractory Follicular and Aggressive B-cell Lymphoma
Conditions: Follicular Lymphoma Patients (Phase IB);   Follicular and Agressive (DLBCL&MCL) B-cell Lymphoma Patients (Phase II)
Intervention: Drug: Lenalidomide and GA101
11 Recruiting Alternating Thalidomide and Lenalidomide Therapy Plus Rituximab (THRiL) as Initial Treatment for Patients With CLL
Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: thalidomide;   Drug: lenalidomide;   Biological: rituximab
12 Recruiting Study of Ibrutinib in Combination With Rituximab and Lenalidomide in Previously Untreated Subjects With Follicular Lymphoma and Marginal Zone Lymphoma
Conditions: Lymphoma;   Follicular Lymphoma (FL)
Interventions: Drug: Lenalidomide;   Drug: Rituximab;   Drug: Ibrutinib
13 Recruiting Maintenance Lenalidomide in Lymphoma
Condition: Lymphoma
Intervention: Drug: Lenalidomide
14 Recruiting A Study to Evaluate the Safety and Efficacy of Lenalidomide With MOR00208 in Patients With R-R DLBCL
Condition: Diffuse Large B-cell Lymphoma
Interventions: Drug: MOR00208;   Drug: Lenalidomide
15 Recruiting Brentuximab Vedotin and Lenalidomide for Relapsed or Refractory Diffuse Large B-cell Lymphoma
Condition: Lymphoma, Large B-Cell, Diffuse
Interventions: Drug: Brentuximab vedotin;   Drug: Lenalidomide
16 Not yet recruiting Phase II Study of Durvalumab in Combination With Lenalidomide in Relapsed/Refractory NK-T-cell Lymphoma
Condition: LYMPHOMA
Interventions: Drug: Durvalumab;   Drug: Lenali
17 Recruiting A Trial of Ibrutinib, Lenalidomide and Rituximab for Patients With Relapsed/Refractory Mantle Cell Lymphoma
Condition: Relapsed/Refractory Mantle Cell Lymphoma
Interventions: Drug: Lenalidomide;   Drug: Ibrutinib;   Drug: Rituximab
18 Recruiting Clarithromycin + Lenalidomide Combination: a Full Oral Treatment for Patients With Relapsed/Refractory Extranodal Marginal Zone Lymphoma
Condition: Mucosa Associated Lymphoid Tissue (MALT) Lymphoma
Intervention: Drug: clarithromycin and lenalidomide
19 Recruiting Smart Start: Study of Rituximab, Lenalidomide, and Ibrutinib Combined With Chemotherapy For Patients With High Risk Diffuse Large B-Cell Lymphoma
Condition: Lymphoma
Interventions: Drug: Rituximab;   Drug: Ibrutinib;   Drug: Lenalidomide;   Drug: Etoposide;   Drug: Prednisone;   Drug: Vincristine;   Drug: Cyclophosphamide;   Drug: Doxorubicin
20 Recruiting Dose Finding Study of Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Condition: Mantle Cell Lymphoma
Interventions: Drug: Lenalidomide;   Drug: Ibrutinib;   Drug: Rituximab

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.